Medicine donations from pharmaceutical companies to those in need can land well-intentioned donors in hot water if certain principles are not followed.

Private healthcare facilities in low- and middle-income countries may not have all medical supplies in stock, but collaboration mitigates individual clinic level shortages. Policy design should not ignore this.

Cross-learning between the corporate world and non-profits helps both sectors to best serve their stakeholders.

Could creating shared value be the next stage of evolution for CSR? The pharmaceutical industry shows how it can work.

About four years ago, INSEAD’s new dean asked me to set up a research centre bringing together all existing initiatives related to the role of business in society. The man had a clear vision: sustainable enterprise would become an important trend in the years ahead.

With the UN SDGs as a guide, how can non-profits and NGOs do their work while considering long-term impact?

Diagnostic capabilities and coordination among and within countries can mean the difference between life and death.

A simple way of thinking about medical criticality, supply chain risk and their interactions can lead to more sustainable solutions for drug shortages.

Nearly eradicated 20 years ago, tuberculosis has since re-emerged at the top of the world’s most deadly infectious diseases list.

Building local capabilities and supply chains is half the battle in winning the war on pandemics.